Literature DB >> 6721469

Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B.

G Lopez-Berestein, R L Hopfer, R Mehta, K Mehta, E M Hersh, R L Juliano.   

Abstract

The efficacy of liposome-encapsulated amphotericin B in the prophylaxis of disseminated Candida albicans infections in neutropenic mice was studied. The administration of liposome-encapsulated amphotericin B was associated with protection against infection with C. albicans when used at doses of greater than or equal to 2 mg of amphotericin B per kg of body weight. Neither empty liposomes nor free amphotericin B showed prophylactic efficacy.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6721469      PMCID： PMC185519          DOI： 10.1128/AAC.25.3.366

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases.

Authors:  C Singer; M H Kaplan; D Armstrong
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

Review 3.  Infectious complications in the cancer patient.

Authors:  G P Bodey
Journal:  Curr Probl Cancer       Date:  1977-06       Impact factor: 3.187

4.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

Review 5.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

6.  Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis.

Authors:  G Lopez-Berestein; R Mehta; R Hopfer; K Mehta; E M Hersh; R Juliano
Journal:  Cancer Drug Deliv       Date:  1983

7.  Nosocomial infections in the immunocompromised adult.

Authors:  L S Young
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965
  7 in total
  11 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

3.  Effect of liposomal amphotericin B on murine macrophages and lymphocytes.

Authors:  R T Mehta; K Mehta; G Lopez-Berestein; R L Juliano
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

4.  Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.

Authors:  R L Hopfer; R Mehta; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 5.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 6.  Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; P M Melissen; W van Vianen; E W van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

7.  Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.

Authors:  J J Schindler; R P Warren; S D Allen; M K Jackson
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Successful treatment of invasive aspergillosis in a heart transplant patient.

Authors:  B Radovancevic; O H Frazier; L O Gentry; O U Okereke; D A Cooley
Journal:  Tex Heart Inst J       Date:  1985-09

10.  Development of amphotericin B liposomes bearing antibody specific to Candida albicans.

Authors:  D R Hospenthal; A L Rogers; G L Mills
Journal:  Mycopathologia       Date:  1988-01       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.